trv120027
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01187836)
Timeline
Indications
Mechanism of action
- Beta-arrestin-1AGONIST
ARRB1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sar-arg-val-tyr-ile-his-pro-ala
- sarcosine-arginyl-valyl-tyrosyl-isoleucyl-histidyl-prolyl-alanine
- trv027
- trv027
- trv027
- trv120027
- trv120027
- trv120027
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01966601 | Phase 2 | Dec 1, 2013 | Trevena Inc. |
| NCT01444872 | Phase 1 | Aug 1, 2011 | Trevena Inc. |
| NCT01187836 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2010 | Trevena Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Trevena Inc. | For profit | 3 | 3 | 2 | 2010 |
1 organizations
Page 1 / 1